alpha-Bisabolone oxide A is an oxygenated sesquiterpene regularly reported in German chamomile essential oil, where it functions mainly as a compositional and chemotype marker rather than a well-studied standalone active. Live sources support its identity, CAS-linked chemistry, repeated occurrence in chamomile profiles, and inclusion among major constituents in multiple population studies, but isolated mechanism, human data, and constituent-specific safety literature remain thin. For AromaForge, it is best framed as a chamomile-linked marker with mixture-level biological context and explicit evidence gaps.
Chemical identity and composition
PubChem resolves Bisabolone oxide A to CID 91700388 with formula C15H24O2 and an oxygenated sesquiterpene oxanone structure. The chamomile-derived-ingredients CIR review and multiple chamomile composition papers both describe bisabolone oxide A as one of the recognized chemotype-defining constituents of chamomile oil, with reported abundance ranging from trace levels up to roughly 13.6% in some reviewed samples and even higher in certain Iranian populations.
Aroma and practical use
- Use the recorded warm herbal, chamomile-like, soft woody descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2019 study of twelve Iranian Matricaria chamomilla populations reported alpha-bisabolone oxide A as the major volatile constituent in most populations, ranging from 45.64% to 65.41%.
The abstract presents alpha-bisabolone oxide A dominance as a population-level chemotype result and links those profiles to ecological and antiradical comparisons across the sampled populations.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2018 chamomile essential-oil study reported a Pharmacopeia-grade oil containing alpha-bisabolone oxide A at 5.8% while testing antimicrobial combinations and toxicity in vitro.
The antimicrobial and toxicity outcomes in that paper were measured for the oil and its combinations rather than attributed to alpha-bisabolone oxide A alone.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2014 steam-distillation kinetics study identified alpha-bisabolone oxide A among the major quantified chamomile-oil constituents and reported that its yield increased with longer distillation time.
The abstract describes distillation time as a practical modifier of chamomile oil composition, supporting use of alpha-bisabolone oxide A as a process-sensitive composition marker.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Screening assumption (family fallback). It is not a verified constituent-specific exposure limit.
model fallback · Tisserand Institute — general ketone-class caution guidanceNo authoritative constituent-specific dermal limit, IFRA restriction, or human safety trial was located for isolated alpha-bisabolone oxide A in this research pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Safety framing should default to parent-oil context because the accessible literature located here is dominated by chamomile-oil composition and mixture studies rather than single-compound toxicology.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
no_isolated_mechanism_established
No primary source located in this pass established a constituent-specific molecular mechanism for isolated alpha-bisabolone oxide A. Mechanistic discussion in accessible literature remains indirect and mixture-weighted.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No isolated alpha-bisabolone oxide A human, animal, or cell-study pharmacology was verified in this pass.
- Mechanism evidence remains indirect and mixture-weighted rather than constituent-specific.
- Public safety evidence is too thin to justify a numeric topical-use limit for the isolated constituent.
- No IFRA Standard, Tisserand monograph, or RIFM safety assessment specific to isolated alpha-Bisabolone oxide A (CAS 22567-38-0) was located in this pass; accessible sources describe occurrence in chamomile chemotypes only.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.